Table 1.
Patients clinical characteristics (n = 16).
| Gender | Age | Disease types | disease status | Donor type | peripheral blood(MNC×10^8/kg/CD34+×10^6/kg) | Bone marrow(MNC×10^8/kg/CD34+×10^6/kg) | Neutrophil implantation(d) | Platelet implantation(d) | implantation | Transplantation related complications | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Male | 58 | ALL | CR | UMD | 6.4/3.9 | – | 21 | 25 | 100% | CMV |
| 2 | female | 48 | AA | – | haplo-HSCT | 9.46/6.95 | 2.6/0.45 | 18 | – | 99.50% | Pulmonary infection |
| 3 | Male | 39 | AML | CR | UMD | 9.36/2.6 | – | 22 | 16 | 100% | CMV |
| 4 | Male | 45 | AA | – | SMD | 10.9/6.8 | – | 13 | 13 | 99.50% | – |
| 5 | Male | 23 | AML | CR | haplo-HSCT | 15.4/6.1 | 2.1/0.97 | 22 | 20 | 100% | – |
| 6 | female | 23 | AML | CR | UMD | 12.8/3.52 | – | 67 | – | 98% | Tuberculosis、GVHD |
| 7 | Male | 48 | AML | CR | haplo-HSCT | 13.3/6.07 | 4.52/0.85 | 21 | 21 | 100% | Fungal infection |
| 8 | female | 53 | AML | CR | SMD9/10 | 10/7 | – | 13 | 13 | 99.50% | CMV |
| 9 | female | 58 | AML | CR | haplo-HSCT | 11/6.1 | 2.4/1.07 | 25 | – | 99% | CMV、GVHD |
| 10 | Male | 46 | ALL | CR | haplo-HSCT | 8.7/3.68 | 3.84/0.8 | 21 | 21 | 99.50% | CMV |
| 11 | female | 54 | AML | CR (MRD+) | SMD | 10.4/5.4 | – | 20 | 20 | 100% | CMV |
| 12 | Male | 34 | AML | CR (MRD+) | haplo-HSCT | 8.4/6.7 | 2.9/0.4 | 18 | 18 | 99.50% | CMV、Fungal infection |
| 13 | Male | 34 | MDS | – | haplo-HSCT | 13.5/5.8 | 1.88/0.11 | 14 | 19 | 100% | encephalitis infection |
| 14 | female | 30 | AA | – | haplo-HSCT | 10.1/8.7 | 4.8/1.3 | 21 | 37 | 100% | CMV、GVHD、hemorrhage |
| 15 | female | 47 | AML | CR | haplo-HSCT | 10.9/4.2 | 3.3/1.1 | 15 | 15 | 100% | CMV、Fungal infection |
| 16 | Male | 16 | ALL | CR | haplo-HSCT | 8.67/7.07 | 4.16/0.83 | 20 | 20 | 100% | CMV、GVHD |
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; AA, aplastic anemia; MDS, myelodysplastic syndrome; UMD, Matched unrelated donor; SMD, matched sibling donor; haplo-HSCT, Haploidentical Hematopoietic Stem Cell Transplantation; CMV, cytomegalovirus; GVHD, graft versus host disease.